All In Biotech

NDA 021752 · Gilead

Truvada

Emtricitabine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Accelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Aug 2, 2004

Approved uses

6

Original approval plus efficacy supplements

Registered trials

684

198 Phase 3, 28 recruiting

FAERS reports

45,437

38,317 serious, 1,835 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not...

What it is approved for

From the label in effect Jul 16, 2025.

HIV-1 Treatment ( 1.1 ) TRUVADA is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg. HIV-1 PrEP ( 1.2 ): TRUVADA is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP. 1.1 Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg [see Clinical Studies (14) ] . 1.2 HIV-1 Pre-Exposure Prophylaxis (PrEP) TRUVADA is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .

Mechanism: TRUVADA is a fixed-dose combination of antiviral drugs FTC and TDF [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TRUVADA · EMTRICITABINE 167MG; TENOFOVIR DISOPROXIL FUMARATE 250MG · TABLET, ORAL · Prescription · TE AB
  • TRUVADA · EMTRICITABINE 100MG; TENOFOVIR DISOPROXIL FUMARATE 150MG · TABLET, ORAL · Prescription · TE AB
  • TRUVADA · EMTRICITABINE 133MG; TENOFOVIR DISOPROXIL FUMARATE 200MG · TABLET, ORAL · Prescription · TE AB
  • TRUVADA · EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Emtricitabine" as an intervention, any sponsor and status, largest first.

All 684 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bone density decreased16,618
  • chronic kidney disease10,394
  • osteonecrosis9,164
  • bone loss9,115
  • renal failure9,049
  • multiple fractures8,191
  • tooth loss8,163
  • renal injury8,010
  • osteoporosis7,326
  • skeletal injury7,181
  • pain6,586
  • emotional distress6,351

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
2005150
2006395
2007518
2008906
20091,204
20101,078
2011986
20121,141
20131,243
20141,476
20151,661
20161,419
20171,295
20181,667
20192,994
202014,655
20214,707
20222,977
20231,589
20241,567
20251,346
2026462

Recalls

1 FDA enforcement reports for this application.

  • Sep 30, 2014 · Class III · Terminated

    Presence of Foreign Substance: Truvada was found to contain small red silicone rubber particulates.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Truvada (Emtricitabine/Tenofovir (Tdf))

2024 spending

$3.9M

Beneficiaries

578

1,932 claims

Per beneficiary

$6,728

$57.85 per unit

View as table
YearSpending
2020$164,325,556
2021$36,297,990
2022$9,076,232
2023$5,529,868
2024$3,888,802

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 977 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.